RANI Stock Catalyst: Rani Therapeutics and ProGen Demonstrate Bioequivalence of Oral GLP-1/GLP-2 Agonist

Jul 14, 2025 · 5:02am ET

Late breaking presentation at ENDO 2025

Max move

+72.1%

High of day $1.18

Sparker timei

5:02am ET

RANI · Jul 14, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Rani Therapeutics Holdings, Inc. and ProGen announced on July 14, 2025, a late breaking presentation at ENDO 2025. The presentation demonstrated the bioequivalence of a novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill.

The study showcased the effectiveness of RaniPill in delivering the bispecific agonist, highlighting its potential as an alternative to traditional subcutaneous methods.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time RANI sparks.

Download Sniper App →

Catch the next RANI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →